首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
A Case of Duodenocaval Fistula in the Setting of Respiratory Failure Initially Confused for Transfusion-Related Acute Lung Injury. 一例因输血相关急性肺损伤引起呼吸衰竭的十二指肠腔瘘。
Pub Date : 2023-07-01 Epub Date: 2023-07-14 DOI: 10.12788/fp.0391
Gaurav Suryawanshi, Aaron Boothby, Richard Dykowski

Background: A duodenocaval fistula is seen when a connection exists between the duodenum and the inferior vena cava. It is a rare entity that presents a diagnostic challenge due to its nonspecific presenting symptoms and often is found only during a laparotomy or autopsy.

Case presentation: A 37-year-old man initially presented to the hospital for melena but went into cardiac arrest before undergoing an esophagogastroduodenoscopy. Unfortunately, a duodenocaval fistula was only found during the autopsy.

Conclusions: Duodenocaval fistula is a diagnostic challenge as it may present with nonspecific findings concerning for other etiologies. We want to highlight that although rare, duodenocaval fistula should be considered for patients who present with gastrointestinal bleeding and hypoxic respiratory failure.

背景:当十二指肠和下腔静脉之间存在连接时,可以看到十二指肠腔静脉瘘。它是一种罕见的实体,由于其非特异性的表现症状而引起诊断挑战,通常只有在剖腹手术或尸检中才能发现。病例介绍:一名37岁男子最初因黑便被送往医院,但在接受食管胃十二指肠镜检查之前心脏骤停。不幸的是,十二指肠腔瘘是在尸检时才发现的。结论:十二指肠腔静脉瘘是一个诊断挑战,因为它可能表现出与其他病因有关的非特异性发现。我们想强调的是,尽管十二指肠腔瘘很罕见,但对于出现胃肠道出血和缺氧性呼吸衰竭的患者,应考虑使用十二指肠腔瘘。
{"title":"A Case of Duodenocaval Fistula in the Setting of Respiratory Failure Initially Confused for Transfusion-Related Acute Lung Injury.","authors":"Gaurav Suryawanshi,&nbsp;Aaron Boothby,&nbsp;Richard Dykowski","doi":"10.12788/fp.0391","DOIUrl":"10.12788/fp.0391","url":null,"abstract":"<p><strong>Background: </strong>A duodenocaval fistula is seen when a connection exists between the duodenum and the inferior vena cava. It is a rare entity that presents a diagnostic challenge due to its nonspecific presenting symptoms and often is found only during a laparotomy or autopsy.</p><p><strong>Case presentation: </strong>A 37-year-old man initially presented to the hospital for melena but went into cardiac arrest before undergoing an esophagogastroduodenoscopy. Unfortunately, a duodenocaval fistula was only found during the autopsy.</p><p><strong>Conclusions: </strong>Duodenocaval fistula is a diagnostic challenge as it may present with nonspecific findings concerning for other etiologies. We want to highlight that although rare, duodenocaval fistula should be considered for patients who present with gastrointestinal bleeding and hypoxic respiratory failure.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588995/pdf/fp-40-07-228.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Incidence After Emergency Department Visit. 急诊科就诊后的新冠肺炎发病率。
Pub Date : 2023-07-01 Epub Date: 2023-07-12 DOI: 10.12788/fp.0384
Jonathan Balakumar, My-Phuong Pham, Selene Mak, Kathleen Yip

Background: The emergency department (ED) at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) saw a decrease in the number of visits during the early stages of the COVID-19 pandemic. Little is known whether risk mitigation procedures may help reduce the spread of COVID-19 infections for veterans visiting the ED. Therefore, we reviewed patient visits to the ED for diagnoses other than COVID-19 to assess whether these patients had an increased COVID-19 positivity rate within 21 days of the initial visit.

Observations: Risk mitigation procedures instituted by the VAGLAHS ED included a COVID-19 outdoor testing tent, immediate isolation of persons under investigation for COVID-19, disinfection protocols between high-risk patient encounters, dedicated training in donning and doffing personal protective equipment, implementation of 2-physician airway teams for COVID-19 intubations, use of electronic tablets to communicate with COVID-19 patients, and implementation of social distancing initiatives in the waiting room to minimize COVID-19 exposures. The average positivity rate at the VAGLAHS ED during this time frame was 0% to 6.7%, compared with 6.9% to 33.3% within the wider VAGLAHS.

Conclusions: Implementing risk mitigation procedures in the VAGLAHS ED helped minimize exposure and subsequent diagnosis of COVID-19 for veterans who visited the VAGLAHS ED for symptoms not associated with COVID-19 infection. Seeking acute medical care in the ED did not put patients at higher risk of contracting COVID-19.

背景:在新冠肺炎大流行的早期阶段,退伍军人事务大洛杉矶医疗保健系统(VAGLAHS)的急诊科(ED)的就诊次数有所减少。目前尚不清楚风险缓解程序是否有助于减少访问急诊室的退伍军人感染新冠肺炎的传播。因此,我们审查了患者访问急诊室进行新冠肺炎以外的诊断,以评估这些患者在首次访视后21天内新冠肺炎阳性率是否增加。观察结果:VAGLAHS ED制定的风险缓解程序包括新冠肺炎室外测试帐篷、对新冠肺炎接受调查的人员立即隔离、高风险患者接触之间的消毒协议、穿戴和脱下个人防护设备的专门培训、新冠肺炎插管的2个物理气道团队的实施、,使用电子平板电脑与新冠肺炎患者交流,并在候诊室实施社交距离举措,以最大限度地减少新冠肺炎暴露。在这段时间内,VAGLAHS ED的平均阳性率为0%至6.7%,而在更广泛的VAGLAHS ED中为6.9%至33.3%。在急诊室寻求急性医疗护理并没有使患者感染新冠肺炎的风险更高。
{"title":"COVID-19 Incidence After Emergency Department Visit.","authors":"Jonathan Balakumar,&nbsp;My-Phuong Pham,&nbsp;Selene Mak,&nbsp;Kathleen Yip","doi":"10.12788/fp.0384","DOIUrl":"10.12788/fp.0384","url":null,"abstract":"<p><strong>Background: </strong>The emergency department (ED) at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) saw a decrease in the number of visits during the early stages of the COVID-19 pandemic. Little is known whether risk mitigation procedures may help reduce the spread of COVID-19 infections for veterans visiting the ED. Therefore, we reviewed patient visits to the ED for diagnoses other than COVID-19 to assess whether these patients had an increased COVID-19 positivity rate within 21 days of the initial visit.</p><p><strong>Observations: </strong>Risk mitigation procedures instituted by the VAGLAHS ED included a COVID-19 outdoor testing tent, immediate isolation of persons under investigation for COVID-19, disinfection protocols between high-risk patient encounters, dedicated training in donning and doffing personal protective equipment, implementation of 2-physician airway teams for COVID-19 intubations, use of electronic tablets to communicate with COVID-19 patients, and implementation of social distancing initiatives in the waiting room to minimize COVID-19 exposures. The average positivity rate at the VAGLAHS ED during this time frame was 0% to 6.7%, compared with 6.9% to 33.3% within the wider VAGLAHS.</p><p><strong>Conclusions: </strong>Implementing risk mitigation procedures in the VAGLAHS ED helped minimize exposure and subsequent diagnosis of COVID-19 for veterans who visited the VAGLAHS ED for symptoms not associated with COVID-19 infection. Seeking acute medical care in the ED did not put patients at higher risk of contracting COVID-19.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588997/pdf/fp-40-07-224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transition to Tenecteplase From t-PA for Acute Ischemic Stroke at Walter Reed National Military Medical Center 沃尔特里德国家军事医疗中心急性缺血性卒中由t-PA转为替奈普酶治疗
Cole P Denkensohn
Background: Tissue plasminogen activator (t-PA) has been the standard IV thrombolytic drug used in acute ischemic stroke treatment since 1995. Tenecteplase has been available for use in acute myocardial infarction and has been endorsed by the American Heart Association stroke guidelines as an alternative to t-PA. Observations: A systematic process to safely transition from t-PA to tenecteplase for acute ischemic stroke was undertaken at Walter Reed National Military Medical Center. The process to implement tenecteplase required extensive training and education for staff physicians, nurses, pharmacists, radiologists, trainees, and the rapid response team. There are a variety of benefits and implementation challenges to consider when transitioning thrombolytic therapy for institutional use in acute ischemic stroke. Conclusions: Evidence supports the transition from t-PA to tenecteplase for acute ischemic stroke. Successful transition required months of preparation involving multidisciplinary meetings that included neurology, nursing, pharmacy, radiology, rapid response teams, critical care, and emergency medicine. Safeguards must be implemented to avoid dosing errors that can lead to life-threatening adverse events.
背景:组织型纤溶酶原激活剂(t-PA)自1995年以来一直是急性缺血性脑卒中治疗的标准静脉溶栓药物。Tenecteplase已可用于急性心肌梗死,并已被美国心脏协会卒中指南认可为t-PA的替代品。观察:在沃尔特里德国家军事医学中心进行了一个系统的过程,安全地从t-PA过渡到替替普酶治疗急性缺血性卒中。实施tenecteplase的过程需要对工作人员(医生、护士、药剂师、放射科医生、受训人员和快速反应小组)进行广泛的培训和教育。在将溶栓治疗转变为机构应用于急性缺血性卒中时,有各种各样的益处和实施挑战需要考虑。结论:有证据支持急性缺血性卒中从t-PA到替尼替酶的转变。成功的过渡需要几个月的准备工作,涉及多学科会议,包括神经病学、护理学、药学、放射学、快速反应小组、重症监护和急诊医学。必须实施保障措施,以避免可能导致危及生命的不良事件的给药错误。
{"title":"Transition to Tenecteplase From t-PA for Acute Ischemic Stroke at Walter Reed National Military Medical Center","authors":"Cole P Denkensohn","doi":"10.12788/fp.0351","DOIUrl":"https://doi.org/10.12788/fp.0351","url":null,"abstract":"Background: Tissue plasminogen activator (t-PA) has been the standard IV thrombolytic drug used in acute ischemic stroke treatment since 1995. Tenecteplase has been available for use in acute myocardial infarction and has been endorsed by the American Heart Association stroke guidelines as an alternative to t-PA. Observations: A systematic process to safely transition from t-PA to tenecteplase for acute ischemic stroke was undertaken at Walter Reed National Military Medical Center. The process to implement tenecteplase required extensive training and education for staff physicians, nurses, pharmacists, radiologists, trainees, and the rapid response team. There are a variety of benefits and implementation challenges to consider when transitioning thrombolytic therapy for institutional use in acute ischemic stroke. Conclusions: Evidence supports the transition from t-PA to tenecteplase for acute ischemic stroke. Successful transition required months of preparation involving multidisciplinary meetings that included neurology, nursing, pharmacy, radiology, rapid response teams, critical care, and emergency medicine. Safeguards must be implemented to avoid dosing errors that can lead to life-threatening adverse events.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91144935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of IV Edaravone Use in the Management of Amyotrophic Lateral Sclerosis 静脉注射依达拉奉治疗肌萎缩性侧索硬化的疗效评价
Christopher Damlos
Background: Edaravone has been shown to slow functional degeneration of amyotrophic lateral sclerosis (ALS). The primary objective of this study was to assess ALS disease progression in veterans on IV edaravone compared with veterans who received standard of care. Methods: This retrospective case-control study was conducted at a large, academic US Department of Veteran Affairs medical center. The primary endpoint was the change in baseline Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores after 6 months of IV edaravone compared with standard-of-care ALS management. The secondary outcomes included change in ALSFRS-R scores, percent forced vital capacity (%FVC) and speech intelligibility stage (SIS) 3 to 24 months after initiation of therapy, duration of edaravone completed (months), time to death (months), and safety outcomes. Results: Twenty-one edaravone and 42 standard-of-care patients were evaluated. No difference was noted in ALSFRS-R at 6 months between the edaravone and standard-of-care groups ( P = .84). Additionally, no difference was noted in change from baseline %FVC, change from baseline SIS, and time to death between the 2 groups ( P > .05). No safety events were reported in either group. Conclusions: No difference was noted in the rate of ALS disease progression between patients who received IV edaravone vs standard of care.
背景:依达拉奉已被证明可以减缓肌萎缩性侧索硬化症(ALS)的功能退化。本研究的主要目的是评估静脉注射依达拉奉的退伍军人与接受标准治疗的退伍军人的ALS疾病进展情况。方法:本回顾性病例对照研究在美国退伍军人事务部医学中心进行。主要终点是与ALS标准治疗相比,静脉注射依达拉奉6个月后,基线修订肌萎缩侧索硬化症功能评定量表(ALSFRS-R)评分的变化。次要结果包括ALSFRS-R评分的变化,治疗开始后3至24个月的用力肺活量百分比(%FVC)和言语可理解阶段(SIS),依达拉丰完成时间(月),死亡时间(月)和安全性结果。结果:对21例依达拉奉患者和42例标准治疗患者进行了评估。依达拉奉组和标准治疗组6个月时ALSFRS-R无差异(P = 0.84)。此外,两组患者FVC的基线变化、SIS的基线变化和死亡时间无差异(P > 0.05)。两组均无安全事件报告。结论:接受静脉依达拉奉治疗的患者与接受标准治疗的患者在ALS疾病进展率方面没有差异。
{"title":"Assessment of IV Edaravone Use in the Management of Amyotrophic Lateral Sclerosis","authors":"Christopher Damlos","doi":"10.12788/fp.0373","DOIUrl":"https://doi.org/10.12788/fp.0373","url":null,"abstract":"Background: Edaravone has been shown to slow functional degeneration of amyotrophic lateral sclerosis (ALS). The primary objective of this study was to assess ALS disease progression in veterans on IV edaravone compared with veterans who received standard of care. Methods: This retrospective case-control study was conducted at a large, academic US Department of Veteran Affairs medical center. The primary endpoint was the change in baseline Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores after 6 months of IV edaravone compared with standard-of-care ALS management. The secondary outcomes included change in ALSFRS-R scores, percent forced vital capacity (%FVC) and speech intelligibility stage (SIS) 3 to 24 months after initiation of therapy, duration of edaravone completed (months), time to death (months), and safety outcomes. Results: Twenty-one edaravone and 42 standard-of-care patients were evaluated. No difference was noted in ALSFRS-R at 6 months between the edaravone and standard-of-care groups ( P = .84). Additionally, no difference was noted in change from baseline %FVC, change from baseline SIS, and time to death between the 2 groups ( P > .05). No safety events were reported in either group. Conclusions: No difference was noted in the rate of ALS disease progression between patients who received IV edaravone vs standard of care.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83027027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discontinuing Disease-Modifying Therapies in Nonactive Secondary Progressive MS: Review of the Evidence 停止治疗非活动性继发性进展性MS:证据回顾
Natasha Antonovich
Background: There are currently no disease-modifying therapies (DMTs) on the market approved for nonactive secondary progressive multiple sclerosis (SPMS), and lifelong DMTs are neither indicated nor supported by evidence. Nevertheless, the discontinuation of DMTs has been a long-debated topic with varied opinions on how and when to discontinue. Observations: This article reviews the current literature regarding the discontinuation of DMTs in nonactive SPMS. Discontinuing DMTs does not seem to have deleterious effects on the nonactive SPMS disease course and may improve quality of life. Conclusions: The growing evidence in this area may make discontinuation of DMTs in nonactive SPMS a less debatable topic, but it is still a major treatment decision that clinicians must thoroughly discuss with the patient to provide high-quality, patient-centered care.
背景:目前市场上还没有批准用于非活动性继发性进行性多发性硬化症(SPMS)的疾病修饰疗法(dmt),并且终身dmt既没有指征也没有证据支持。然而,dmt的停止一直是一个长期争论的话题,关于如何以及何时停止有不同的意见。观察:本文回顾了目前关于非活性SPMS患者停用dmt的文献。停用dmt似乎不会对非活动性SPMS病程产生有害影响,并可能改善生活质量。结论:该领域越来越多的证据可能会使非活动性SPMS患者停用dmt成为一个较少争议的话题,但它仍然是一个主要的治疗决策,临床医生必须与患者充分讨论,以提供高质量的、以患者为中心的护理。
{"title":"Discontinuing Disease-Modifying Therapies in Nonactive Secondary Progressive MS: Review of the Evidence","authors":"Natasha Antonovich","doi":"10.12788/fp.0390","DOIUrl":"https://doi.org/10.12788/fp.0390","url":null,"abstract":"Background: There are currently no disease-modifying therapies (DMTs) on the market approved for nonactive secondary progressive multiple sclerosis (SPMS), and lifelong DMTs are neither indicated nor supported by evidence. Nevertheless, the discontinuation of DMTs has been a long-debated topic with varied opinions on how and when to discontinue. Observations: This article reviews the current literature regarding the discontinuation of DMTs in nonactive SPMS. Discontinuing DMTs does not seem to have deleterious effects on the nonactive SPMS disease course and may improve quality of life. Conclusions: The growing evidence in this area may make discontinuation of DMTs in nonactive SPMS a less debatable topic, but it is still a major treatment decision that clinicians must thoroughly discuss with the patient to provide high-quality, patient-centered care.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90351506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Barriers to Implementation of Telehealth Pre-anesthesia Evaluation Visits in the Department of Veterans Affairs. 退伍军人事务部实施远程医疗麻醉前评估访问的障碍。
Pub Date : 2023-07-01 Epub Date: 2023-07-17 DOI: 10.12788/fp.0387
Atilio Barbeito, Karthik Raghunathan, Samantha Connolly, Edward R Mariano, Jeanna Blitz, Randall S Stafford, Sesh Mudumbai

Background: Evaluations are conducted days or weeks before a scheduled surgical or invasive procedure involving anesthesia to assess patients' preprocedure condition and risk, optimize status, and prepare them for their procedure. The traditional pre-anesthesia evaluation is conducted in person, although telehealth modalities have been used for several years and have accelerated since the advent of the COVID-19 pandemic.

Methods: We surveyed 109 anesthesiology services to understand the barriers and facilitators to the adoption of telephone- and video-based pre-anesthesia evaluation visits within the US Department of Veterans Affairs (VA).

Results: The analysis included 55 responses from 50 facilities. Twenty-two facilities reported using both telephone and video, 11 telephone only, 5 video only, and 12 none of these modalities. For telehealth users, the ability to obtain a history of present illness, the ability to assess for comorbidities, and assess for health habits were rated highest while assessing nutritional status was lowest. Among nonusers of telehealth modalities, barriers to adoption included the inability to perform a physical examination and the inability to obtain vital signs. Respondents not using telephone cited concerns about safety, while respondents not using video also cited lack of information technology and staff support and patient-level barriers.

Conclusions: We found no significant perceived advantages of video over telephone in the ability to conduct routine pre-anesthesia evaluations except for the perceived ability to assess nutritional status. Clinicians with no telehealth experience cited the inability to perform a physical examination and obtain vital signs as the most significant barriers to implementation. Future work should focus on delineating the most appropriate and valuable uses of telehealth for pre-anesthesia evaluation and/or optimization.

背景:评估在涉及麻醉的预定手术或侵入性手术前几天或几周进行,以评估患者的术前状况和风险,优化状态,并为手术做好准备。传统的麻醉前评估是亲自进行的,尽管远程医疗模式已经使用了几年,并且自新冠肺炎大流行以来已经加速。方法:我们调查了109家麻醉服务机构,以了解美国退伍军人事务部(VA)采用电话和视频麻醉前评估访问的障碍和促进因素。结果:分析包括来自50家机构的55份回复。22个设施报告同时使用电话和视频,11个仅使用电话,5个仅使用视频,12个没有使用这些方式。对于远程医疗用户来说,获得当前病史的能力、评估合并症的能力和评估健康习惯的能力被评为最高,而评估营养状况的能力最低。在不使用远程医疗模式的人中,采用的障碍包括无法进行体检和无法获得生命体征。不使用电话的受访者表示担心安全,而不使用视频的受访者还表示缺乏信息技术和员工支持以及患者层面的障碍。结论:我们发现,除了评估营养状况的感知能力外,视频电话在进行常规麻醉前评估的能力方面没有显著的感知优势。没有远程医疗经验的临床医生认为,无法进行身体检查和获取生命体征是实施的最大障碍。未来的工作应侧重于描述远程医疗在麻醉前评估和/或优化中最合适和最有价值的用途。
{"title":"Barriers to Implementation of Telehealth Pre-anesthesia Evaluation Visits in the Department of Veterans Affairs.","authors":"Atilio Barbeito,&nbsp;Karthik Raghunathan,&nbsp;Samantha Connolly,&nbsp;Edward R Mariano,&nbsp;Jeanna Blitz,&nbsp;Randall S Stafford,&nbsp;Sesh Mudumbai","doi":"10.12788/fp.0387","DOIUrl":"10.12788/fp.0387","url":null,"abstract":"<p><strong>Background: </strong>Evaluations are conducted days or weeks before a scheduled surgical or invasive procedure involving anesthesia to assess patients' preprocedure condition and risk, optimize status, and prepare them for their procedure. The traditional pre-anesthesia evaluation is conducted in person, although telehealth modalities have been used for several years and have accelerated since the advent of the COVID-19 pandemic.</p><p><strong>Methods: </strong>We surveyed 109 anesthesiology services to understand the barriers and facilitators to the adoption of telephone- and video-based pre-anesthesia evaluation visits within the US Department of Veterans Affairs (VA).</p><p><strong>Results: </strong>The analysis included 55 responses from 50 facilities. Twenty-two facilities reported using both telephone and video, 11 telephone only, 5 video only, and 12 none of these modalities. For telehealth users, the ability to obtain a history of present illness, the ability to assess for comorbidities, and assess for health habits were rated highest while assessing nutritional status was lowest. Among nonusers of telehealth modalities, barriers to adoption included the inability to perform a physical examination and the inability to obtain vital signs. Respondents not using telephone cited concerns about safety, while respondents not using video also cited lack of information technology and staff support and patient-level barriers.</p><p><strong>Conclusions: </strong>We found no significant perceived advantages of video over telephone in the ability to conduct routine pre-anesthesia evaluations except for the perceived ability to assess nutritional status. Clinicians with no telehealth experience cited the inability to perform a physical examination and obtain vital signs as the most significant barriers to implementation. Future work should focus on delineating the most appropriate and valuable uses of telehealth for pre-anesthesia evaluation and/or optimization.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588996/pdf/fp-40-07-210.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fireworks, Veterans, and PTSD: The Ironies of the Fourth of July. 烟花、退伍军人和创伤后应激障碍:七月四日的讽刺。
Pub Date : 2023-07-01 Epub Date: 2023-07-12 DOI: 10.12788/fp.0394
Cynthia Geppert
{"title":"Fireworks, Veterans, and PTSD: The Ironies of the Fourth of July.","authors":"Cynthia Geppert","doi":"10.12788/fp.0394","DOIUrl":"10.12788/fp.0394","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588998/pdf/fp-40-07-208.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacist-Led Management of HIV PrEP Within the Veterans Health Administration. 退伍军人健康管理局药剂师领导的HIV PrEP管理。
Pub Date : 2023-07-01 Epub Date: 2023-05-22 DOI: 10.12788/fp.0379
Madison A Cameron, Jenna Kawamoto, Troy A Shahoumian, Pamela S Belperio

Background: Uptake and access to HIV preexposure prophylaxis (PrEP) is key to reducing incident HIV infections. Pharmacists are one of the most accessible health care professionals in the United States and are well suited to address this need.

Observations: We describe a model of care at the Veterans Affairs Greater Los Angeles Healthcare System in which clinical pharmacist practitioners developed and implemented a pharmacy-led PrEP clinic colocated within an infectious disease clinic. Veterans Health Administration clinical pharmacists provide direct patient care under a scope of practice that includes ordering and interpreting laboratory tests and providing PrEP prescriptions. To improve access and patient acceptability, we also used novel telemedicine modes of care to ensure flexible appointment scheduling.

Conclusions: This model can be used by other federal and community-based health care organizations to implement interdisciplinary pharmacist-managed PrEP clinics and expand telehealth modalities to deliver outpatient services.

背景:接受和获得HIV预存预防(PrEP)是减少HIV感染事件的关键。药剂师是美国最容易获得的医疗保健专业人员之一,非常适合满足这一需求。观察:我们描述了退伍军人事务大洛杉矶医疗保健系统的一种护理模式,在该模式中,临床药剂师从业者开发并实施了一个由药房领导的PrEP诊所,该诊所与传染病诊所共存。退伍军人健康管理局临床药剂师在执业范围内提供直接的患者护理,包括订购和解释实验室测试以及提供PrEP处方。为了提高访问和患者的可接受性,我们还使用了新的远程医疗护理模式,以确保灵活的预约安排。结论:该模式可供其他联邦和社区医疗保健组织用于实施跨学科药剂师管理的PrEP诊所,并扩展远程医疗模式以提供门诊服务。
{"title":"Pharmacist-Led Management of HIV PrEP Within the Veterans Health Administration.","authors":"Madison A Cameron,&nbsp;Jenna Kawamoto,&nbsp;Troy A Shahoumian,&nbsp;Pamela S Belperio","doi":"10.12788/fp.0379","DOIUrl":"10.12788/fp.0379","url":null,"abstract":"<p><strong>Background: </strong>Uptake and access to HIV preexposure prophylaxis (PrEP) is key to reducing incident HIV infections. Pharmacists are one of the most accessible health care professionals in the United States and are well suited to address this need.</p><p><strong>Observations: </strong>We describe a model of care at the Veterans Affairs Greater Los Angeles Healthcare System in which clinical pharmacist practitioners developed and implemented a pharmacy-led PrEP clinic colocated within an infectious disease clinic. Veterans Health Administration clinical pharmacists provide direct patient care under a scope of practice that includes ordering and interpreting laboratory tests and providing PrEP prescriptions. To improve access and patient acceptability, we also used novel telemedicine modes of care to ensure flexible appointment scheduling.</p><p><strong>Conclusions: </strong>This model can be used by other federal and community-based health care organizations to implement interdisciplinary pharmacist-managed PrEP clinics and expand telehealth modalities to deliver outpatient services.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588999/pdf/fp-40-07-218.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Critical Value of Telepathology in the COVID-19 Era. 远程病理学在新冠肺炎时代的关键价值。
Pub Date : 2023-06-01 Epub Date: 2023-06-13 DOI: 10.12788/fp.0381
Jeffrey M Petersen, Nirag Jhala, Darshana N Jhala

Background: Telepathology, which includes the use of telecommunication links, helps enable transmission of digital pathology images for primary diagnosis, quality assurance, education, research, or second opinion diagnoses.

Observations: This review covers all aspects of telepathology implementation, including the selection of platforms, budgets and regulations, validation, implementation, education, quality monitoring, and the potential to improve practice. Considering the long-term trends, the lessons of the COVID-19 pandemic, and the potential for future pandemics or other disasters, the validation and implementation of telepathology remains a reasonable choice for laboratories looking to improve their practice.

Conclusions: Though barriers to implementation exist, there are potential benefits, such as the wide spectrum of uses like frozen section, telecytology, primary diagnosis, and second opinions. Telepathology represents an innovation that may transform the future of pathology practice.

背景:远程病理学,包括使用电信链路,有助于传输数字病理学图像,用于初级诊断、质量保证、教育、研究或第二意见诊断。观察:这篇综述涵盖了远程病理学实施的各个方面,包括平台的选择、预算和法规、验证、实施、教育、质量监控以及改进实践的潜力。考虑到长期趋势、新冠肺炎大流行的教训以及未来大流行或其他灾难的可能性,远程病理学的验证和实施对于寻求改进实践的实验室来说仍然是一个合理的选择。结论:尽管实施存在障碍,但仍有潜在的好处,如冷冻切片、远程细胞术、初级诊断和第二种意见等广泛的用途。远程病理学代表了一种可能改变病理学实践未来的创新。
{"title":"The Critical Value of Telepathology in the COVID-19 Era.","authors":"Jeffrey M Petersen,&nbsp;Nirag Jhala,&nbsp;Darshana N Jhala","doi":"10.12788/fp.0381","DOIUrl":"10.12788/fp.0381","url":null,"abstract":"<p><strong>Background: </strong>Telepathology, which includes the use of telecommunication links, helps enable transmission of digital pathology images for primary diagnosis, quality assurance, education, research, or second opinion diagnoses.</p><p><strong>Observations: </strong>This review covers all aspects of telepathology implementation, including the selection of platforms, budgets and regulations, validation, implementation, education, quality monitoring, and the potential to improve practice. Considering the long-term trends, the lessons of the COVID-19 pandemic, and the potential for future pandemics or other disasters, the validation and implementation of telepathology remains a reasonable choice for laboratories looking to improve their practice.</p><p><strong>Conclusions: </strong>Though barriers to implementation exist, there are potential benefits, such as the wide spectrum of uses like frozen section, telecytology, primary diagnosis, and second opinions. Telepathology represents an innovation that may transform the future of pathology practice.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584409/pdf/fp-40-06-186.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty Trends in an Older Veteran Subpopulation 1 Year Prior and Into the COVID-19 Pandemic Using CAN Scores. 使用CAN评分的新冠肺炎大流行前和进入前1年老年退伍军人亚群的脆弱趋势。
Pub Date : 2023-06-01 Epub Date: 2023-06-14 DOI: 10.12788/fp.0385
Nalini S Bhalla, Janet Fawcett

Background: We studied the effects of the first year of the COVID-19 pandemic on frailty trends in a subset of older veterans at the Phoenix Veterans Affairs Health Care System.

Methods: We identified 3538 and 6103 veterans aged 70 to 75 years as of February 8, 2019, with a calculated Care Assessment Need (CAN) score of ≥ 75 for 1-year mortality and hospitalization, respectively. After excluding veterans with insufficient 2020 and 2021 data, we compared the difference in 1-year mortality and hospitalization CAN scores from 2019 to 2020 with 2020 to 2021 using a paired t test.

Results: The difference in mean (SD) 1-year mortality CAN scores from 2020 to 2021 was 0.2 (13.4) when compared with the previous year's -4.9 (12.5) (P < .0001), indicating increased frailty. The difference in 1-year hospitalization CAN scores from 2020 to 2021 was -1.5 (12.0) when compared with the previous year's -2.8 (9.9) (P < .0001).

Conclusions: Frailty in our veteran subpopulation as calculated by 1-year mortality CAN scores increased in the first year of the COVID-19 pandemic when compared with a recovering trend the previous year.

背景:我们在凤凰城退伍军人事务医疗保健系统研究了新冠肺炎大流行第一年对一部分老年退伍军人虚弱趋势的影响。方法:我们确定了截至2019年2月8日年龄在70至75岁之间的3538名和6103名退伍军人,1年死亡率和住院治疗的护理评估需求(CAN)计算得分分别≥75。在排除2020年和2021年数据不足的退伍军人后,我们使用配对t检验比较了2019年至2020年与2020年至2021年1年死亡率和住院CAN评分的差异。结果:与前一年的-4.9(12.5)(P<.0001)相比,2020年至2021年的平均(SD)1年死亡率CAN评分差异为0.2(13.4),表明虚弱程度增加。与前一年的-2.8(9.9)相比,2020年至2021年的1年住院CAN评分差异为-1.5(12.0)(P<.0001)。
{"title":"Frailty Trends in an Older Veteran Subpopulation 1 Year Prior and Into the COVID-19 Pandemic Using CAN Scores.","authors":"Nalini S Bhalla,&nbsp;Janet Fawcett","doi":"10.12788/fp.0385","DOIUrl":"10.12788/fp.0385","url":null,"abstract":"<p><strong>Background: </strong>We studied the effects of the first year of the COVID-19 pandemic on frailty trends in a subset of older veterans at the Phoenix Veterans Affairs Health Care System.</p><p><strong>Methods: </strong>We identified 3538 and 6103 veterans aged 70 to 75 years as of February 8, 2019, with a calculated Care Assessment Need (CAN) score of ≥ 75 for 1-year mortality and hospitalization, respectively. After excluding veterans with insufficient 2020 and 2021 data, we compared the difference in 1-year mortality and hospitalization CAN scores from 2019 to 2020 with 2020 to 2021 using a paired <i>t</i> test.</p><p><strong>Results: </strong>The difference in mean (SD) 1-year mortality CAN scores from 2020 to 2021 was 0.2 (13.4) when compared with the previous year's -4.9 (12.5) (<i>P</i> < .0001), indicating increased frailty. The difference in 1-year hospitalization CAN scores from 2020 to 2021 was -1.5 (12.0) when compared with the previous year's -2.8 (9.9) (<i>P</i> < .0001).</p><p><strong>Conclusions: </strong>Frailty in our veteran subpopulation as calculated by 1-year mortality CAN scores increased in the first year of the COVID-19 pandemic when compared with a recovering trend the previous year.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584405/pdf/fp-40-06-194.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1